Literature DB >> 7512010

B7/BB1 provides an important costimulatory signal for CD3-mediated T lymphocyte proliferation in patients with systemic lupus erythematosus (SLE).

P P Sfikakis1, R Oglesby, P Sfikakis, G C Tsokos.   

Abstract

Successful T cell activation via the T cell receptor (TCR)/CD3 complex requires at least one contact-dependent second signal delivered by costimulatory molecules, including the B7/BB1 molecule, that are present on antigen-presenting cells (APC). SLE is characterized by multiple complex lymphocyte abnormalities of undefined molecular origin. It is currently unclear whether an intrinsic defect of T cell or an underlying APC dysfunction is responsible for defective in vitro proliferation of T cells from patients with SLE. We planned the present experiments to ask whether the TCR/CD3-mediated and B7/BB1-costimulated T cell proliferation is normal in these patients. We used enriched T cell populations that were stimulated with an anti-CD3 MoAb in the presence of controlled quantities of functional B7/BB1 antigen. Freshly isolated T cells from 17 SLE patients (10 and seven patients with either active or inactive disease, respectively) and 11 normal individuals were cocultured with irradiated B7/BB1-transfected P815 cells or parental P815 cells in the presence of OKT3 MoAb at optimal and suboptimal concentrations for 2.5-7 days. Normal or SLE T cells responded similarly to stimulation via anti-CD3, in the absence of B7/BB1 antigen. A several-fold increase in T cell proliferation in the presence of B7/BB1 antigen was observed. Proliferation was inhibited in the presence of anti-B7/BB1 MoAb, but not with control MoAbs. Interestingly, dose-response curves and time kinetics of B7/BB1 costimulation were similar in T cells from patients with either active or inactive SLE at the time of study, and normal individuals. In addition, no differences in the IL-2 receptor release by T cells cultured under these conditions were observed between SLE patients and normal individuals. These results demonstrate that CD28 signalling is not intrinsically impaired in patients with SLE; further studies to investigate whether abnormal B7/BB1 expression is involved in the autoimmune process are needed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7512010      PMCID: PMC1534533          DOI: 10.1111/j.1365-2249.1994.tb06221.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  47 in total

1.  Responsiveness of systemic lupus erythematosus T cells to signals provided through LCA T200 (CD45) and T1 (CD5) antigens.

Authors:  J Martorell; J Font; I Rojo; R Vilella; M Ingelmo; J Vives
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

2.  B7, a B-cell-restricted antigen that identifies preactivated B cells.

Authors:  A S Freedman; G Freeman; J C Horowitz; J Daley; L M Nadler
Journal:  J Immunol       Date:  1987-11-15       Impact factor: 5.422

Review 3.  The T cell receptor/CD3 complex: a dynamic protein ensemble.

Authors:  H Clevers; B Alarcon; T Wileman; C Terhorst
Journal:  Annu Rev Immunol       Date:  1988       Impact factor: 28.527

4.  The lupus activity criteria count (LACC).

Authors:  M B Urowitz; D D Gladman; E C Tozman; C H Goldsmith
Journal:  J Rheumatol       Date:  1984-12       Impact factor: 4.666

5.  Interleukin 2 deficiencies in rheumatoid arthritis and systemic lupus erythematosus.

Authors:  N Miyasaka; T Nakamura; I J Russell; N Talal
Journal:  Clin Immunol Immunopathol       Date:  1984-04

6.  Soluble interleukin-2 receptors in systemic lupus erythematosus.

Authors:  R E Wolf; W G Brelsford
Journal:  Arthritis Rheum       Date:  1988-06

7.  In vitro correction of the interleukin 2 defect of autoimmune mice.

Authors:  T J Santoro; T A Luger; E S Ravache; J S Smolen; J J Oppenheim; A D Steinberg
Journal:  Eur J Immunol       Date:  1983-07       Impact factor: 5.532

8.  Lpr T cell hyporesponsiveness to mitogens linked to deficient receptor-stimulated phosphoinositide hydrolysis.

Authors:  W Scholz; N Isakov; M I Mally; A N Theofilopoulos; A Altman
Journal:  J Biol Chem       Date:  1988-03-15       Impact factor: 5.157

9.  Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro.

Authors:  L A Rubin; C C Kurman; M E Fritz; W E Biddison; B Boutin; R Yarchoan; D L Nelson
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

10.  The interleukin 2 secretion defect in vitro in systemic lupus erythematosus is reversible in rested cultured T cells.

Authors:  Y P Huang; P A Miescher; R H Zubler
Journal:  J Immunol       Date:  1986-12-01       Impact factor: 5.422

View more
  2 in total

Review 1.  Immune cell signaling aberrations in human lupus.

Authors:  S N Liossis; P P Sfikakis; G C Tsokos
Journal:  Immunol Res       Date:  1998-08       Impact factor: 2.829

2.  Human lymphocyte activation is associated with the early and high-level expression of the endogenous lectin CSL at the cell surface.

Authors:  J P Zanetta; J Wantyghem; S Kuchler-Bopp; A Badache; M Aubery
Journal:  Biochem J       Date:  1995-10-15       Impact factor: 3.857

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.